8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Mar 30, 2026·SEC
Bicara Therapeutics Inc. Common Stock(BCAX)Earnings, Financials & Key Ratios
BCAX•NASDAQ
$28.91
Price updated Jul 2, 2026
AboutBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.Show more
- Revenue$0
- EBITDA-$155M-88.9%
- Net Income-$138M-102.9%
- EPS (Diluted)-2.52-101.6%
- ROE-30.88%-61.3%
BCAX Price & Volume
Bicara Therapeutics Inc. Common Stock (BCAX) stock price & volume — 10-year historical chart
Loading chart...
BCAX Growth Metrics
Bicara Therapeutics Inc. Common Stock (BCAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-70.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-68.48%
Return on Capital
10 Years-31.2%
5 Years-31.2%
3 Years-31.2%
Last Year-32.65%
BCAX Recent Earnings
Bicara Therapeutics Inc. Common Stock (BCAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (29%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.93-45.3%
$0.64
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.68+5.6%
$0.72
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.67-21.8%
$0.55
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.50+7.4%
$0.54
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.93vs $0.64-45.3% | — |
| Q2 2026 | Mar 26, 2026 | $0.68vs $0.72+5.6% | — |
| Q4 2025 | Nov 10, 2025 | $0.67vs $0.55-21.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.50vs $0.54+7.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Bicara Therapeutics Inc. Common Stock (BCAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.91 | $1.58B | -11.47 | — | — | -30.88% | — | |
| $38.14 | $7.83B | -13.77 | — | — | -68.16% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $115.07 | $6.73B | -28.27 | -79.35% | -1027.25% | -55.42% | — | |
| $17.92 | $5.57B | -40.73 | — | — | -77.01% | — | |
| $114.20 | $9.32B | -30.95 | -16.72% | -612.17% | -25.02% | — |
Compare BCAX vs Peers
Bicara Therapeutics Inc. Common Stock (BCAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCAX SEC Filings & Documents
Bicara Therapeutics Inc. Common Stock (BCAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BCAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCAX Frequently Asked Questions
Bicara Therapeutics Inc. Common Stock (BCAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BCAX profitable?
Bicara Therapeutics Inc. Common Stock (BCAX) reported a net loss of $157.3M for fiscal year 2025.
Dividend & Returns
What is BCAX's return on equity?
Bicara Therapeutics Inc. Common Stock (BCAX) has a return on equity (ROE) of -30.9%. Negative ROE indicates the company is unprofitable.
What is Bicara Therapeutics Inc. Common Stock's free cash flow?
Bicara Therapeutics Inc. Common Stock (BCAX) had negative free cash flow of $116.6M in fiscal year 2025, likely due to heavy capital investments.